Fidelity Disruptive Medicine ETFFMED
FMED
0
Funds holding %
of 7,363 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
14% more funds holding
Funds holding: 7 [Q3] → 8 (+1) [Q4]
0.07% more ownership
Funds ownership: 59.71% [Q3] → 59.77% (+0.07%) [Q4]
3% less capital invested
Capital invested by funds: $33.3M [Q3] → $32.1M (-$1.15M) [Q4]
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Research analyst outlook
We haven’t received any recent analyst ratings for FMED.
Financial journalist opinion
Positive
ETF Trends
2 months ago
As Biotech Outlook Grows Healthier, Look to Disruptive ETF FMED
Could now be the time to invest in biotech? The space, which performed well in 2020 and 2021, dropped off in the interim amid high interest rates and slowing deal-making.
Positive
ETF Trends
8 months ago
An Advisor's Guide to Fidelity's Disruptive ETF Suite
Thematic investing continues to garner attention at the midyear point on sustained artificial intelligence interest. For advisors and investors looking to diversify their thematic holdings, the Disruptive ETF suite from Fidelity offers strategies cutting across several sectors.
Positive
ETF Trends
1 year ago
Eye Disruptive Medicine ETF FMED to Start 2024
Could healthcare innovation be one potent opportunity area to start 2024? Healthcare investing wasn't necessarily the best in 2023.
Charts implemented using Lightweight Charts™